| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C7H4BrN3O2 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
3-Bromo-7-nitroindazole is a potent, selective inhibitor of neuronal nitric oxide synthase (nNOS) that affects synthesis of the intercellular messenger nitric oxide (NO) throughout the body and brain. It can be used in research on metabolic and neurological diseases such as diabetes, stroke and depression[1][2][3]. It is supplied as a light yellow to yellow solid (C7H4BrN3O2, MW 242.03) at 99.78% purity.
Physical & Chemical Properties
| CAS Number | 74209-34-0 |
|---|---|
| Molecular Formula | C7H4BrN3O2 |
| Molecular Weight | 242.03 g/mol |
| Purity | 99.78% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | O=[N+](C1=CC=CC2=C1NN=C2Br)[O-] |
| Target | nNOS |
| Signaling Pathway | Immunology/Inflammation |
| Solubility | In Vitro: DMSO: 100 mg/mL (413.17 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (413.17 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (10.33 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Data provided by the manufacturer.
In Vivo
Spatial learning and memory are impaired in rats by 3-Bromo-7-nitroindazole (5-20 mg/kg, i.p., daily for 5 days)[1]. In diabetic stroke rats, 3-Bromo-7-nitroindazole (3-30 mg/kg, i.p.) attenuates brain ischemic injury[2]. In rats, 3-Bromo-7-nitroindazole (20 mg/kg, i.p., daily for 5 weeks) inhibits depression-like behavior induced by chronic unpredictable mild stress (CUMS)[3].
| Animal Model | Wistar rats[1] |
|---|---|
| Dosage | 5, 10 and 20 mg/kg |
| Administration | Intraperitoneally injection, daily for 5 days |
| Result | Impaired the acquisition of the MWM task. Impaired the probe trial. Decreased the increased brain-derived neurotrophic factor (BDNF) mRNA expression in the hippocampus. Had no effects on locomotor activity and blood pressure. |
| Animal Model | Type 2 diabetic rats induced by feeding high-fat diet and streptozotocin with MCAO[2] |
|---|---|
| Dosage | 3, 10 and 30 mg/kg |
| Administration | Intraperitoneally injection |
| Result | Inhibited the cerebral infarct, edema volume. Improved functional recovery of neurological deficits. Decreased DNA fragmentation with a concomitant reduction of GRP78 and CHOP. |
| Animal Model | Chronic unpredictable mild stress (CUMS)-induced rats models[3] |
|---|---|
| Dosage | 20 mg/kg |
| Administration | Intraperitoneally injection, daily for 5 weeks |
| Result | Reduced sucrose preference, body-weight and locomotor activity. Increased immobility time in the FST. Increased BDNF protein levels in the CA1 and CA3 regions of the hippocampus. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. Anal Chem 2025 Jun 3;97(21):11099-11109. PMID: 40401576
